# OnCo record biolinerx (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/biolinerx/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "biolinerx" ;
  schema:name "BioLineRx"@en ;
  schema:alternateName "BioLineRx, Ltd."@en, "BioLineRx Ltd."@en ;
  schema:description "BioLineRx is an Israeli company whose CXCR4 inhibitor motixafortide (Aphexda) was approved in the United States in 2023 to mobilise stem cells for autologous transplant in multiple myeloma, and which tests the drug with pembrolizumab in pancreatic cancer."@en ;
  schema:url <https://onco.cc/companies/biolinerx/>, <https://www.biolinerx.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/BioLineRx> ;
  owl:sameAs <http://www.wikidata.org/entity/Q4914627> ;
  schema:citation <https://www.biolinerx.com>, <https://clinicaltrials.gov/search?lead=BioLineRx>, <https://en.wikipedia.org/wiki/BioLineRx> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "IL" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/pancreatic/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/>, <https://onco.cc/fronts/targeted-therapy/> ;
  onco:targets <https://onco.cc/targets/cxcr4/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/filgrastim/> ;
  onco:terms <https://onco.cc/terms/autologous-transplant/> ;
  onco:trials <https://onco.cc/trials/nct03246529/> .